Pyrimidine containing epidermal growth factor receptor kinase inhibitors: Synthesis and biological evaluation
Files
Date
2017
Journal Title
Journal ISSN
Volume Title
Publisher
Blackwell Publishing Ltd
Abstract
Structure-based design and synthesis of pyrimidine containing reversible epidermal growth factor receptor (EGFR) inhibitors 1a?d are reported. The compounds (1a?d) inhibited the EGFR kinase activity in vitro with IC50 range 740?nm to 3??m. mRNA expression of EGFR downstream target genes, that is twist, c-fos and aurora were found to be altered upon treatment with compounds 1a?d. The compounds 1a?d exhibited excellent anticancer activity at low micromolar level (3.2?9??m) in lung, colon and breast cancer cell lines. Furthermore, compounds induced the alteration in mitochondrial membrane potential and reactive oxygen species level and. Selected compound 1b was found to increase sub-G1 population indicative of cell death, the mode of cell death was apoptotic as evident from Annexin V verses propidium iodide assay. Molecular modelling further helped to investigate the binding recognition pattern of the compounds in ATP binding EGFR domain similar to erlotinib and dissimilar to WZ4002. ? 2017 John Wiley & Sons A/S.
Description
Keywords
Pyrimidine, Reactive oxygen metabolite, Unclassified drug, Antineoplastic agent, Epidermal growth factor receptor, Protein kinase inhibitor, Pyrimidine
Citation
Joshi, G., Nayyar, H., Kalra, S., Sharma, P., Munshi, A., Singh, S., & Kumar, R. (2017). Pyrimidine containing epidermal growth factor receptor kinase inhibitors: Synthesis and biological evaluation. Chemical Biology and Drug Design, 90(5), 995-1006. doi: 10.1111/cbdd.13027